Skip Navigation
Contact Us
Search:
Search Toggle
EN
中
Toggle Navigation
Search:
Search Submit
ABOUT US
Our Company
Our Team
expertise
Pipeline
Pipeline
FWD1509
FWD1802
News
Careers
Join Our Team
Job Opportunities
NEWS
Scroll Down
The class I-targeting, oral HDAC inhibitor OKI-179 increases tumor regressions when combined with the MEK inhibitor binimetinib in models of NRAS melanoma